Immunosuppressive treatment results in patients with primary IgA nephropathy in Turkiye; the data from TSN-GOLD working group

References

• Turkmen A, Sumnu A, Cebeci E, et al. Epidemiological features of primary glomerular disease in turkiye: a multicenter study by the Turkish society of nephrology glomerular diseases working group. BMC Nephrol. 2020;21(1):1.
   Web of Science ®Google Scholar
• Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402–10.
   PubMed Web of Science ®Google Scholar
• Coppo R, D’Amico G. Factors predicting progression of IgA nephropathies. J Nephrol. 2005;18(5):503–512.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1–S276.
   PubMedGoogle Scholar
• Zhang YM, Lv JC, Wong MG, Zhang H, Perkovic V. Glucocorticoids for IgA nephropathy-pro. Kidney Int. 2023;103(4):666–669.
   PubMed Web of Science ®Google Scholar
• Novak J, Rizk D, Takahashi K,. New insights into the pathogenesis of IgA nephropathy. Kidney Dis (Basel). 2015;1(1):8–18.
   PubMed Web of Science ®Google Scholar
• Kant S, Kronbichler A, Sharma P, Geetha DAdvances in understanding of pathogenesis and treatment of ımmune-Mediated kidney disease: a review. Am J Kidney Dis. 2022;79(4):582–600.
   PubMed Web of Science ®Google Scholar
• Natale P, Palmer SC, Ruospo M,. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev. 2020;3(3):CD003965.
   PubMedGoogle Scholar
• Lv J, Wong MG, Hladunewich MA, et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients With IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022;327(19):1888–1898.
   PubMed Web of Science ®Google Scholar
• Hou FF, Xie D, Wang J, et al. Effectiveness of mycophenolate mofetil Among patients With progressive IgA nephropathy: a randomized clinical trial. JAMA Netw Open. 2023;6(2):e2254054.
   PubMed Web of Science ®Google Scholar
• Liang M, Xiong L, Li A, et al. The effectiveness and safety of corticosteroid therapy for IgA nephropathy with crescents: a prospective, randomized, controlled study. BMC Nephrol. 2022;23(1):40.
   PubMed Web of Science ®Google Scholar
• Zhao H, Li Y, Sun J, et al. Immunosuppression versus supportive care on kidney outcomes in IgA nephropathy in the Real-World setting. Clin J Am Soc Nephrol. 2023;18(9):1186–1194.
   PubMed Web of Science ®Google Scholar
• Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus ımmunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225–2236.
   PubMed Web of Science ®Google Scholar
• Rauen T, Fitzner C, Eitner F, et al. Effects of two ımmunosuppressive treatment protocols for IgA nephropathy. J Am Soc Nephrol. 2018;29(1):317–325.
   PubMed Web of Science ®Google Scholar
• Rauen T, Wied S, Fitzner C, et al. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020;98(4):1044–1052.
   PubMed Web of Science ®Google Scholar
• Lv J, Xu D, Perkovic V, et al. Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol. 2012;23(6):1108–1116.
   PubMed Web of Science ®Google Scholar
• Lv J, Zhang H, Wong MG, et al. Effect of oral methylprednisolone on clinical outcomes in patients With IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017;318(5):432–442.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH. A new equation to estimate glomerular filtration rate Ann Intern Med. 2009;150(9):604–612.
   PubMed Web of Science ®Google Scholar
• Turkish society of nephrology consent report on diagnosis and treatment of primary glomerular diseases. Ankara (Turkiye): Turkish Society of Nephrology; 2019.
   Google Scholar
• Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15(1):157–163.
   PubMed Web of Science ®Google Scholar
• Manno C, Torres DD, Rossini M, Pesce F, Schena FPRandomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009;24(12):3694–3701.
   PubMed Web of Science ®Google Scholar
• Lv J, Zhang H, Chen Y, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2009;53(1):26–32.
   PubMed Web of Science ®Google Scholar
• Gleeson PJ, O’Shaughnessy MM, Barratt J. IgA nephropathy in adults-treatment standard. Nephrol Dial Transplant. 2023;38(11):2464–2473.
   PubMed Web of Science ®Google Scholar
• Hou JH, Le WB, Chen N, et al. Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Dis. 2017;69(6):788–795.
   PubMed Web of Science ®Google Scholar
• Cambier A, Troyanov S, Tesar V, et al. Indication for corticosteroids in IgA nephropathy: validation in the European VALIGA cohort of a treatment score based on the oxford classification. Nephrol Dial Transplant. 2022;37(6):1195–1197.
   PubMed Web of Science ®Google Scholar
• Haaskjold YL, Lura NG, Bjørneklett R, et al. Long-term follow-up of IgA nephropathy: clinicopathological features and predictors of outcomes. Clin Kidney J. 2023;16(12):2514–2522.
   PubMed Web of Science ®Google Scholar
• Yu F, Zhu X, Yuan S, et al. Predictive value of Sub classification of focal segmental glomerular sclerosis in oxford classification of IgA nephropathy. Ann Med. 2021;53(1):587–595.
   PubMed Web of Science ®Google Scholar